Drugs / 13-PCV Booster
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02545868 | Oct 2015 → Feb 2017 | relapsing-remitting multiple sclerosis | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-PCV Booster | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02545868 ↗ |
| Known as | Prevnar | “The OCR1 group received Prevnar (13-valent conjugate pneumococcal vaccine) 4 weeks after 23-PPV” PMID 32727835 ↗ Jul 2020 |
| Modality | Vaccine | “Prevnar (13-valent conjugate pneumococcal vaccine) 4 weeks after 23-PPV” PMID 32727835 ↗ Jul 2020 |
| Route | Intramuscular | “IM injection” NCT02545868 ↗ |